Buy Memantine (Namenda) Cas 19982-08-2

Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer’s disease.^[10][11][8] It is taken by mouth.^[10][8]

Common side effects include headache, constipation, sleepiness, and dizziness.^[10][11] Severe side effects may include blood clots, psychosis, and heart failure.^[11] It is believed to work by acting on NMDA receptors, working as a pore blocker of these ion channels.^[8][10]

Memantine was first discovered in 1963.^[8][12][13] It was approved for medical use in Germany in 1989, in the European Union in 2002, and in the United States in 2003.^[13][10][14] It is available as a generic medication.^[11] In 2023, it was the 145th most commonly prescribed medication in the United States, with more than 3 million prescriptions.^[15][16]

Memantine is used to treat moderate-to-severe Alzheimer’s disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors.^[17][18] One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.^[19]

Memantine has been associated with a modest improvement;^[20] with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer’s disease.^[21][22] There does not appear to be any benefit in mild disease.^[23]

Memantine when added to donepezil in those with moderate-to-severe dementia resulted in “limited improvements” in a 2017 review.^[24] The UK National Institute for Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia.^[25]

Memantine has been recommended for use by professional organization consensus to prevent neurocognitive decline after whole brain radiotherapy.^[26]

Memantine is, in general, well tolerated.^[20] Common adverse drug reactions (≥1% of people) include confusion, dizziness, drowsiness, headache, insomnia, agitation, and/or hallucinations. Less common adverse effects include vomiting, anxiety, hypertonia, cystitis, and increased libido.^[20][27]

Like many other NMDA receptor antagonists, memantine behaves as a dissociative anesthetic at supratherapeutic doses.^[28] Despite isolated reports, recreational use of memantine is rare due to the drug’s long duration and limited availability.^[28] Additionally, memantine seems to lack effects such as euphoria or hallucinations.^[29]

Memantine appears to be generally well tolerated by children with autism spectrum disorder.^[30]

Memantine is an uncompetitive NMDA receptor antagonist, with an IC50 binding affinity of ~500-1,000 nM (0.5-1 μM),^[31] but displays higher potency at extrasynaptic NMDA receptors (IC50 = ~22 nM),^[31] suggesting preferential inhibition of pathological glutamatergic signaling.

Memantine also exhibits activity at several other